January 2015

Teva v. Sandoz

By: Justin Crotty & Andreas Baltatzis  |   January 27, 2015

The Supreme Court has redefined the structure of appellate review in patent cases in a way which enhances the role of district courts, diminishes the discretion of the Federal Circuit and has important but uncertain implications for all intellectual property practitioners. Teva Pharmaceuticals U.S.A., Inc., et al. v. Sandoz, Inc. et al. considers the standard of review on appeal when issues in claim construction have evidentiary underpinnings.